Senior Scientific Director
Takeda Pharmaceuticals
Cambridge, Massachusetts
Dean Bottino received his PhD in Applied Mathematics from Tulane University in 1996. His academic work at Tulane, and subsequently at University of Utah and UC Berkeley, consisted of spatiotemporal simulations of eukaryotic cell motility and chemotaxis. Dr. Bottino then moved into industry, joining Physiome Sciences in 2001, co-founding the BioAnalytics Group LLC in 2003, then moving on to Novartis in 2005, Roche in 2011 and Takeda (Millennium) in 2013. He has specialized in preclinical and clinical modeling and simulation in oncology since 2005. His more recent contributions to the field include characterizing paradoxical behavior of RECIST progression-free survival (Johnson et al, EJC 2019) and proposing novel dose optimization methodology for oncology combination therapy (Bottino et al, CCR 2019).
Tuesday, October 24, 2023
1:30 PM – 2:30 PM ET